Therapeutic potential of cystic fibrosis transmembrane conductance regulator (CFTR) inhibitors in polycystic kidney disease

BioDrugs

Volumn 23, Issue 4, 2009, Pages 203-216

  Li, Hongyu ^a   Sheppard, David N ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 [(3 TRIFLUOROMETHYL)PHENYL] 5 [(4 (1H TETRAZOL 5 YL)PHENYL)METHYLENE] 2 THIOXO 4 THIAZOLIDINONE; BUMETANIDE; GATX1 PEPTIDE TOXIN; GENISTEIN; GLIBENCLAMIDE; MEMBRANE PROTEIN; METFORMIN; MOZAVAPTAN; N (2 NAPHTHALENYL) [(3,5 DIBROMO 2,4 DIHYDROXYPHENYL)METHYLENE]GLYCINE HYDRAZIDE; NIFLUMIC ACID; PH N (2 NAPHTHALENYL) [(3,5 DIBROMO 2,4 DIHYDROXYPHENYL)METHYLENE]GLYCINE HYDRAZIDE; PHENYLGLYCINE; PHENYLGLYCINE 01 [68]; PHLOXINE; POLYCYSTIN 2; PYROPHOSPHATE; SCORPION VENOM; SODIUM CHLORIDE; TETRAZOLO 3 [(3 TRIFLUOROMETHYL)PHENYL] 5 [(4 (1H TETRAZOL 5 YL)PHENYL)METHYLENE] 2 THIOXO 4 THIAZOLIDINONE; TOLVAPTAN; TOXIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; VRT 532 [69]; VX 770; WATER;

CHEMICAL STRUCTURE; CLINICAL TRIAL; CONFORMATIONAL TRANSITION; CYSTIC FIBROSIS; DIARRHEA; DISEASE MODEL; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; EDEMA; HIGH THROUGHPUT SCREENING; HUMAN; HYPERTENSION; HYPONATREMIA; INTROSPECTION; KIDNEY HYPERTROPHY; KIDNEY POLYCYSTIC DISEASE; KNOWLEDGE; LIVER POLYCYSTIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; WATER FLOW;

ANIMALS; BENZOIC ACIDS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DRUG DISCOVERY; HUMANS; POLYCYSTIC KIDNEY DISEASES; THIAZOLIDINES;

EID: 69249209814     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11313570-000000000-00000     Document Type: Review

References (110)

1. Torres VE, Harris PC, Pirson Y. Autosomal dominat polycystic kidney disease. Lancet 2007; 369: 1287-1301
2. Wilson PD, Goilav B. Cystic disease of the kidney. Annu Rev Pathol Mech Dis 2007; 2: 341-368
3. Delmas P. Polycystins: polymodal receptor/ion-channel cellular sensors. Pflügers Arch 2005; 451: 264-276
4. Delmas P, Nomura H, Li X, et al. Constitutive activation of G-proteins by polycystin-1 is antagonized by polycystin-2. J Biol Chem 2002; 277: 11276-11283
5. 2+-permeable nonselective cation channel. Proc Natl Acad Sci U S A 2001; 98: 1182-1187
6. Nauli SM, Alenghat FJ, Luo Y, et al. Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat Genet 2003; 33: 129-137
7. Roitbak T, Ward CJ, Harris PC, et al. A polycystin-1 multiprotein complex is disrupted in polycystic kidney disease cells. Mol Biol Cell 2004; 15: 1334-1346
8. Cai Y, Maeda Y, Cedzich A, et al. Identification and characterization of polycystin-2, the PKD2 gene product. J Biol Chem 1999; 274: 28557-28565
9. Boletta A, Qian F, Onuchic LF, et al. Polycystin-1, the gene product of PKD1, induces resistance to apoptosis and spontaneous tubulogenesis in MDCK cells. Mol Cell 2000; 6: 1267-1273
10. Hanaoka K, Guggino WB. cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells. J Am Soc Nephrol 2000; 11: 1179-1187
11. Yamaguchi T, Pelling JC, Ramaswamy NT, et al. cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int 2000; 57: 1460-1471
12. Sullivan LP, Wallace DP, Grantham JJ. Chloride and fluid secretion in polycystic kidney disease. J Am Soc Nephrol 1998; 9: 903-916
13. Ye M, Grantham JJ. The secretion of fluid by renal cysts from patients with autosomal dominant polycystic kidney disease. N Engl J Med 1993; 329: 310-313
14. Welsh MJ, Ramsey BW, Accurso F, et al. Cystic fibrosis. In: Scriver CR, Beaudet AL, Sly WS, et al., editors. The metabolic and molecular basis of inherited disease. 8th ed. New York: McGraw-Hill Inc., 2001: 5121-5188
15. - secretion and cyst growth by cultured ADPKD cells. J Am Soc Nephrol 2002; 13: 2619-2627
16. Lansdell KA, Cai Z, Kidd JF, et al. Two mechanisms of genistein inhibition of cystic fibrosis transmembrane conductance regulator Cl- channels expressed in murine cell line. J Physiol 2000; 524: 317-330
17. Wang F, Zeltwanger S, Yang ICH, et al. Actions of genistein on cystic fibrosis transmembrane conductance regulator channel gating: evidence for two binding sites with opposite effects. J Gen Physiol 1998; 111: 477-490
18. Li H, Findlay IA, Sheppard DN. The relationship between cell proliferation, Cl- secretion, and renal cyst growth: a study using CFTR inhibitors. Kidney Int 2004; 66: 1926-1938
19. Quinton PM. Chloride impermeability in cystic fibrosis. Nature 1983; 301: 421-422 work described in this review
20. Riordan JR, Rommens JM, Kerem B-S, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245: 1066-1073
21. Anderson MP, Gregory RJ, Thompson S, et al. Demonstration that CFTR is a chloride channel by alteration of its anion selectivity. Science 1991; 253: 202-205
22. Holland IB, Cole SPC, Kuchler K, et al. ABC Proteins: from bacteria to man. London: Academic Press, 2003
23. Sheppard DN, Welsh MJ. Structure and function of the cystic fibrosis transmembrane conductance regulator chloride channel. Physiol Rev 1999; 79 Suppl. 1: S23-45
24. Guggino WB, Stanton BA. New insights into cystic fibrosis: molecular switches that regulate CFTR. Nat Rev Mol Cell Biol 2006; 7: 426-436
25. Morales MM, Carroll TP, Moria T, et al. Both the wild type and a functional isoform of CFTR are expressed in kidney. Am J Physiol 1996; 270: F1038-1048
26. Husted RF, Volk KA, Sigmund RD, et al. Anion secretion by the inner medullary collecting duct: evidence for involvement of the cystic fibrosis transmembrane conductance regulator. J Clin Invest 1995; 95: 644-650
27. Stanton BA. Cystic fibrosis transmembrane conductance regulator (CFTR) and renal function. Wien Klin Wochenschr 1997; 109: 457-464
28. Uchida S, Sasaki S. Function of chloride channels in the kidney. Annu Rev Physiol 2005; 67: 759-778
29. Brill SR, Ross KE, Davidow CJ, et al. Immunolocalization of ion transport proteins in human autosomal dominant polycystic kidney epithelial cells. Proc Natl Acad Sci U S A 1996; 93: 10206-10211
30. Hanaoka K, Devuyst O, Schwiebert EM, et al. A role for CFTR in human autosomal dominant polycystic kidney disease. Am J Physiol 1996; 270: C389-399
31. Davidow CJ, Maser RL, Rome LA, et al. The cystic fibrosis transmembrane conductance regulator mediates transepithelial fluid secretion by human autosomal dominant polycystic kidney disease epithelium in vitro. Kidney Int 1996; 50: 208-218
32. O'Sullivan DA, typic expression of autosomal dominant polycystic kidney disease. Am J Kidney Dis 1998; 32: 976-983
33. Persu A, Bevuyst O, Lannoy N, et al. CF gene and cystic fibrosis trans-membrane conductance regulator expression in autosomal dominant poly-cystic kidney disease. J Am Soc Nephrol 2000; 11: 2285-2296
34. Haas M, Forbush BI. The Na-K-Cl cotransporter of secretory epithelia. Annu Rev Physiol 2000; 62: 515-534
35. Hallows KR, McCane JE, Kemp BE, et al. Regulation of channel gating by AMP-activated protein kinase modulates cystic fibrosis transmembrane conductance regulator activity in lung submucosal cells. J Biol Chem 2003; 278: 998-1004
36. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167-1174
37. Sheppard DN. CFTR channel pharmacology: novel pore blockers identified by high-throughput screening. J Gen Physiol 2004; 124: 109-113
38. Chen J-H, Cai Z, Li H, et al. Function of CFTR protein: ion transport. In: Bush A, Alton EWFW, Davies JC, et al., editors. Cystic fibrosis in the 21st century. Basel: S Karger AG, 2006: 38-44
39. Sheppard DN, Robinson KA. Mechanism of glibenclamide inhibition of cystic fibrosis transmembrane conductance regulator Cl- channels expressed in a murine cell line. J Physiol 1997; 503: 333-346
40. Hwang T-C, Sheppard DN. Molecular pharmacology of the CFTR Cl-channel. Trends Pharmacol Sci 1999; 20: 448-453
41. Hille B. Ionic channels of excitable membranes. 3rd ed. Sunderland (MA): Sinauer Associates Inc., 2001
42. Linsdell P, Tabcharani JA, Rommens JM, et al. Permeability of wild-type and mutant cystic fibrosis transmembrane conductance regulator chloride channels to polyatomic anions. J Gen Physiol 1997; 110: 355-364 (Pubitemid 27431174)
43. Cheung M, Akabas MH. Identification of cystic fibrosis transmembrane conductance regulator channel-lining residues in and flanking the M6 membrane-spanning segment. Biophys J 1996; 70: 2688-2695
44. Linsdell P, Hanrahan JW. Adenosine triphosphate-dependent asymmetry of anion permeation in the cystic fibrosis transmembrane conductance regulator chloride channel. J Gen Physiol 1998; 111: 601-614
45. Cai Z, Scott-Ward TS, Sheppard DN. Voltage-dependent gating of the cystic fibrosis transmembrane conductance regulator Cl- channel. J Gen Physiol 2003; 122: 605-620
46. Muanprasat C, Sonawane ND, Salinas D, et al. Discovery of glycine hydrazide pore-occluding CFTR inhibitors: mechanism, structure-activity analysis and in vivo efficacy. J Gen Physiol 2004; 124: 125-137
47. Tabcharani JA, Low W, Elie D, et al. Low-conductance chloride channel activated by cAMP in the epithelial cell line T84. FEBS Lett 1990; 270: 157-164
48. Linsdell P, Hanrahan JW. Disulphonic stilbene block of cystic fibrosis transmembrane conductance regulator Cl- channels expressed in a mammalian cell line and its regulation by a critical pore residue. J Physiol 1996; 496: 687-693
49. + channel regulators on cystic fibrosis transmembrane conductance regulator chloride currents. J Gen Physiol 1992; 100: 573-591
50. Linsdell P, Evagelidis A, Hanrahan JW. Molecular determinants of anion selectivity in the cystic fibrosis transmembrane conductance regulator chloride channel pore. Biophys J 2000; 78: 2973-2982 (Pubitemid 30396928)
51. Gupta J, Linsdell P. Point mutations in the pore region directly or indirectly affect glibenclamide block of the CFTR chloride channel. Pflügers Arch 2002; 443: 739-747
52. Linsdell P. Location of a common inhibitor binding site in the cytoplasmic vestibule of the cystic fibrosis transmembrane conductance regulator chloride channel pore. J Biol Chem 2005; 280: 8945-8950
53. St Aubin CN, Zhou J-J, Linsdell P. Identification of a second blocker VE, Gabow PA, et al. Cystic fibrosis and the phenobinding site at the cytoplasmic mouth of the cystic fibrosis transmembrane conductance regulator chloride channel pore. Mol Pharmacol 2007; 71: 1360-1368 (Pubitemid 46658689)
54. St Aubin CN, Linsdell P. Positive charges at the intracellular mouth of the pore regulate anion conduction in the CFTR chloride channel. J Gen Physiol 2006; 128: 535-545
55. Cai Z, Lansdell KA, Sheppard DN. Inhibition of heterologously expressed cystic fibrosis transmembrane conductance regulator Cl- channels by non-sulphonylurea hypoglycaemic agents. Br J Pharmacol 1999; 128: 108-118
56. Zhou Z, Hu S, Hwang T-C. Probing an open CFTR pore with organic anion blockers. J Gen Physiol 2002; 120: 647-662
57. Zhang Z-R, Zeltwanger S, McCarty NA. Steady-state interactions of glib-enclamide with CFTR: evidence for multiple sites in the pore. J Membr Biol 2004; 199: 15-28
58. Gadsby DC, Vergani P, Csanády L. The ABC protein turned chloride channel whose failure causes cystic fibrosis. Nature 2006; 440: 477-483
59. Bompadre SG, Hwang T-C. CFTR: a chloride channel gated by ATP binding and hydrolysis. Sheng Li Xue Bao 2007; 59: 431-442
60. Lewis HA, Buchanan SG, Burley SK, et al. Structure of nucleotide-binding domain 1 of the cystic fibrosis transmembrane conductance regulator. EMBO J 2004; 23: 282-293
61. Dawson RJP, Locher KP. Structure of a bacterial multidrug ABC transporter. Nature 2006; 443: 180-185
62. Aleksandrov L, Aleksandrov AA, Chang X-B, et al. The first nucleotide binding domain of cystic fibrosis transmembrane conductance regulator is a site of stable nucleotide interaction, whereas the second is a site of rapid turnover. J Biol Chem 2002; 277: 15419-15425 (Pubitemid 34967805)
63. Vergani P, Nairn AC, Gadsby DC. On the mechanism of MgATP-dependent gating of CFTR Cl- channels. J Gen Physiol 2003; 120: 17-36
64. Ai T, Bompadre SG, Wang X, et al. Capsaicin potentiates wild-type and mutant cystic fibrosis transmembrane conductance regulator chloride-channel currents. Mol Pharmacol 2004; 65: 1415-1426
65. Cai Z, Taddei A, Sheppard DN. Differential sensitivity of the cystic fibrosis (CF)-associated mutants G551D and G1349D to potentiators of the cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel. J Biol Chem 2006; 281: 1970-1977
66. Zegarra-Moran O, Monteverde M, Galietta LJV, et al. Functional analysis of mutations in the putative binding site for cystic fibrosis transmembrane conductance regulator potentiators: interaction between activation and inhibition. J Biol Chem 2007; 282: 9098-9104
67. Hwang T-C, Wang F, Yang ICH, et al. Genistein potentiates wild-type and deltaF508-CFTR channel activity. Am J Physiol 1997; 273: C988-998
68. Pedemonte N, Sonawane ND, Taddei A, et al. Phenylglycine and sulfonamide correctors of defective DF508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating. Mol Pharmacol 2005; 67: 1797-1807 (Pubitemid 40594181)
69. Van Goor F, Straley KS, Cao D, et al. Rescue of DF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol 2006; 290: L1117-1130
70. Scott-Ward TS, Li H, Schmidt A, et al. Direct block of the cystic fibrosis transmembrane conductance regulator Cl- channel by niflumic acid. Mol Membr Biol 2004; 21: 27-38
71. Scott-Ward TS, Cai Z, Dawson ES, et al. Chimeric constructs endow the human CFTR Cl- channel with the gating behavior of murine CFTR. Proc Natl Acad Sci U S A 2007; 104: 16365-16370
72. Carson MR, Winter MC, Travis SM, et al. Pyrophosphate stimulates wild-type and mutant cystic fibrosis transmembrane conductance regulator Cl - channels. J Biol Chem 1995; 270: 20466-20472
73. Dérand R, Bulteau-Pignoux L, Becq F. The cystic fibrosis mutation G551D alters the non-Michaelis-Menten behaviour of the cystic fibrosis trans-membrane conductance regulator (CFTR) channel and abolishes the inhibitory genistein binding site. J Biol Chem 2002; 277: 35999-36004
74. Fuller MD, Zhang Z-R, Cui G, et al. Inhibition of CFTR channels by a peptide toxin of scorpion venom. Am J Physiol 2004; 287: C1328-1341
75. Fuller MD, Zhang Z-R, Cui G, et al. The block of CFTR by scorpion venom is state-dependent. Biophys J 2005; 89: 3960-3975
76. Fuller MD, Thompson CH, Zhang Z-R, et al. State-dependent inhibition of cystic fibrosis transmembrane conductance regulator chloride channels by a novel peptide toxin. J Biol Chem 2007; 282: 37545-37555
77. Tytgat J, Chandy KG, Garcia ML, et al. A unified nomenclature for short-chain peptides isolated from scorpion venoms: a-KTx molecular subfamilies. Trends Pharmacol Sci 1999; 20: 444-447
78. Ma T, Thiagarajah JR, Yang H, et al. Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. J Clin Invest 2002; 110: 1651-1658
79. Thiagarajah JR, Verkman AS. New drug targets for cholera therapy. Trends Pharmacol Sci 2005; 26: 172-175
80. Sonawane ND, Verkman AS. Thiazolidinone CFTR inhibitors with improved water solubility identified by structure-activity analysis. Bioorg Med Chem 2008; 16: 8187-8195
81. Yang B, Sonawane ND, Zhao D, et al. Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease. J Am Soc Nephrol 2008; 19: 1300-1310
82. Sonawane ND, Hu J, Muanprasat C, et al. Luminally active, nonabsorbable CFTR inhibitors as potential therapy to reduce intestinal fluid loss in cholera. FASEB J 2006; 20: 130-132
83. Sonawane ND, Zhao D, Zegarra-Moran O, et al. Lectin conjugates as potent, nonabsorbable CFTR inhibitors for reducing intestinal fluid secretion in cholera. Gastroenterology 2007; 132: 1234-1244
84. Sonawane ND, Zhao D, Zegarra-Moran O, et al. Nanomolar CFTR inhibition by poreoccluding divalent polyethylene glycolmalonic acid hydrazides. Chem Biol 2008; 15: 718-728
85. Bebök Z, Tousson A, Schwiebert LM, et al. Improved oxygenation promotes CFTR maturation and trafficking in MDCK monolayers. Am J Physiol 2001; 280: C135-145
86. Grantham JJ, Uchic M, Cragoe Jr EJ, et al. Chemical modification of cell proliferation and fluid secretion in renal cysts. Kidney Int 1989; 35: 1379-1389
87. 2alpha; stimulates CFTR activity by PKA- and PKC-dependent phosphorylation. Am J Physiol 1998; 275: C653-660
88. Schultz BD, Singh AK, Devor DC, et al. Pharmacology of CFTR chloride channel activity. Physiol Rev 1999; 79 Suppl. 1: S109-144
89. - channels inferred from analysis of voltage-dependent block. J Biol Chem 2001; 276: 18423-18429
90. Sakaguchi M, Matsuura H, Ehara T. Swelling-induced Cl- current in guinea-pig atrial myocytes: inhibition by glibenclamide. J Physiol 1997; 505: 41-52
91. Wonderlin WF, Strobl JS. Potassium channels, proliferation and G1 progression. J Membr Biol 1996; 154: 91-107
92. Shen M-R, Droogmans G, Eggermont J, et al. Differential expression of volume-regulated anion channels during cell cycle progression of human cervical cancer cells. J Physiol 2000; 529: 385-394
93. Schwiebert EM, Benos DJ, Egan ME, et al. CFTR is a conductance regulator as well as a chloride channel. Physiol Rev 1999; 79 Suppl. 1: S145-166
94. Vennekens R, Trouet D, Vankeerberghen A, et al. Inhibition of volume-regulated anion channels by expression of the cystic fibrosis transmembrane conductance regulator. J Physiol 1999; 515: 75-85 (Pubitemid 29092622)
95. 2+-dependent potassium channels. Proc Natl Acad Sci U S A 2001; 98: 5329-5334
96. 1 of the cell cycle. EMBO J 1992; 11: 875-883
97. - cotransporter-dependent cystic dilation. J Am Soc Nephrol 2006; 17: 3424-3437
98. Ikeda M, Fong P, Cheng J, et al. A regulatory role of polycystin-1 on cystic fibrosis transmembrane conductance regulator plasma membrane expression. Cell Physiol Biochem 2006; 18: 9-20
99. Tanner GA, McQuillan PF, Maxwell MR, et al. An in vitro test of the cell stretch-proliferation hypothesis of renal cyst enlargement. J Am Soc Nephrol 1995; 5: 1230-1241
100. Shibazaki S, Yu Z, Nishio S, et al. Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1. Hum Mol Genet 2008; 17: 1505-1516
101. Torres VE, Wang X, Qian Q, et al. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 2004; 10: 363-364 (Pubitemid 38508512)
102. Wu G, D'AgatiPkd2 results in polycystic kidney disease. Cell 1998; 93: 177-188
103. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral va-sopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355: 2099-2112
104. Rosenberg MF, Kamis AB, Aleksandrov LA, et al. Purification and crystallization of the cystic fibrosis transmembrane conductance regulator (CFTR). J Biol Chem 2004; 279: 39051-39057
105. Mio K, Ogura T, Mio M, et al. Three-dimensional reconstruction of human cystic fibrosis transmembrane conductance regulator chloride channel revealed an ellipsoidal structure with orifices beneath the putative trans-membrane domain. J Biol Chem 2008; 283: 30300-30310
106. Serohijos AWR, Hegedús T, Aleksandrov AA, et al. Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function. Proc Natl Acad Sci U S A 2008; 105: 3256-3261
107. Mornon J-P, Lehn P, Callebaut I. Atomic model of human cystic fibrosis transmembrane conductance regulator: membrane-spanning domains and coupling interfaces. Cell Mol Life Sci 2008; 65: 2594-2612
108. Banales JM, Masyuk TV, Bogert PS, et al. Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease. Am J Pathol 2008; 173: 1637-1646
109. Sheppard DN, Ostedgaard LS, Winter MC, et al. Mechanism of dysfunction of two nucleotide-binding domain mutations in cystic fibrosis transmem-brane conductance regulator that are associated with pancreatic sufficiency. EMBO J 1995; 14: 876-883
110. Nofziger C, Brown KK, Smith CD, et al. PPARg agonists inhibit vasopres-sion-mediated anion transport in the MDCK-C7 cell line. Am J Physiol 2009; 297: F55-62